论文部分内容阅读
目的探讨立体定向放疗联合高强度聚焦超声(high intensity focused ultrasound,HIFU)治疗原发性肝癌的临床效果。方法选择2012年3月—2014年3月收治的原发性肝癌患者94例作为研究对象,随机分为观察组与对照组各47例。对照组单行立体定向放疗,观察组于对照组基础上行HIFU治疗。观察两组患者3、6、9、12个月生存率及不良反应发生情况。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组患者治疗后3、6、12个月生存率分别为93.62%、78.72%、57.45%高于对照组的65.96%、55.32%、36.17%,差异均有统计学意义(均P<0.05)。不良反应方面,观察组恶心呕吐发生率为31.91%,低于对照组的55.32%,差异有统计学意义(P<0.05)。结论原发性肝癌治疗中,采用立体定向放疗联合HIFU具有较好治疗效果,能有效提高患者生存率,安全性较高,值得临床推广运用。
Objective To investigate the clinical effect of stereotactic radiotherapy combined with high intensity focused ultrasound (HIFU) in the treatment of primary liver cancer. Methods Ninety-four patients with primary liver cancer who were admitted from March 2012 to March 2014 were selected as study subjects and randomly divided into observation group (47 cases) and control group (47 cases). Control group of single-row stereotactic radiotherapy, the observation group in the control group on the basis of HIFU treatment. 3,6,9,12 months survival rate and adverse reactions were observed in two groups of patients. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results The survival rates of observation group were 93.62%, 78.72% and 57.45% respectively, which were significantly higher than those of control group (65.96%, 55.32% and 36.17%, respectively) ). Adverse reactions, the observation group nausea and vomiting was 31.91%, lower than the control group of 55.32%, the difference was statistically significant (P <0.05). Conclusions Stereotactic radiotherapy combined with HIFU has a good therapeutic effect in the treatment of primary liver cancer, which can effectively improve the survival rate of patients with high safety and is worthy of clinical promotion and application.